Featured Stock to Focus: Bristol-Myers Squibb Company (BMY)


Bristol-Myers Squibb Company (BMY) belonging to the Medical sector has declined -1.78% and closed its last trading session at $56.29.

The company reported its EPS on 01/26/2017. Currently, the stock has a 1 Year Price Target of $55.46.

The consensus recommendation, according to Zacks Investment research, is 2.27. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 2.31 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.31 and 2.5 respectively.

Bristol-Myers Squibb Company on 01/26/2017 reported its EPS as $0.63 with the analysts projecting the EPS of the stock as $0.67. The company beat the analyst EPS Estimate with the difference of $-0.04. This shows a surprise factor of -6%.

Many analysts have provided their estimated foresights on Bristol-Myers Squibb Company Earnings, with 14 analysts believing the company would generate an Average Estimate of $0.75.

Whereas they predicted High and Low Earnings Estimate as $0.8 and $0.66 respectively. While in the same Quarter Previous year, the Actual EPS was $0.74.

Analysts are also projecting an Average Revenue Estimate for Bristol-Myers Squibb Company as $4.74 Billion in the Current Quarter. This estimate is provided by 12 analysts.

The High Revenue estimate is predicted as 4.92 Billion, while the Low Revenue Estimate prediction stands at 4.55 Billion. The company’s last year sales total was 4.39 Billion.

For the Current Quarter, the growth estimate for Bristol-Myers Squibb Company is 1.4%, while for the Next Quarter the stock growth estimate is 0%.

In the past 5 years, the stock showed growth of 5.73% per annum. While for the next 5 years, the growth estimate is 14.47%.

The Company got Upgrade by Jefferies on 19-Dec-16 from Hold to Buy.

Insider Trades for Bristol-Myers Squibb Company show that the latest trade was made on 9 Mar 2017 where Von Autenried Paul, the Chief Technology Officer completed a transaction type “Buy” in which 2003 shares were traded at a price of $0.

4 Insider Sales transactions were made totaling 378372 shares traded.

21 analysts projected Price Targets for Bristol-Myers Squibb Company. The analysts believe that the company stock price could grow as high as $68. The Low Price target projection by analysts is $42 and the Mean Price Target is $55.46.

Bristol-Myers Squibb Company (BMY) has the market capitalization of $94.16 Billion. The company rocked its 52-Week High of $77.12 on Jul 15, 2016 and touched its 52-Week Low of $46.01 on Jan 26, 2017.

The stock has Return on Assets (ROA) of 13.5 percent. Return on Equity (ROE) stands at 29.2% and Return on Investment (ROI) of 20 percent.

The stock is currently showing YTD performance of -3.04 Percent. The company has Beta Value of 1.08 and ATR value of 1.09. The Weekly and Monthly Volatility stands at 1.88% and 1.91%.